Đang chuẩn bị liên kết để tải về tài liệu:
báo cáo hóa học:" Quality of life and life circumstances in German myasthenia gravis patients"

Tuyển tập các báo cáo nghiên cứu về hóa học được đăng trên tạp chí hóa học đề tài : Quality of life and life circumstances in German myasthenia gravis patients | Twork et al. Health and Quality of Life Outcomes 2010 8 129 http www.hqlo.eom content 8 1 129 HEALTH AND QUALITY of life outcomes RESEARCH Open Access Quality of life and life circumstances in German myasthenia gravis patients 1t 1 t 1 2 1 Sabine Twork Susanne Wiesmeth Jorg Klewer Dieter Pohlau Joachim Kugler Abstract Background Myasthenia gravis MG is a chronic neuromuscular disease. Advances in medical therapy have continuously increased the life expectancy of MG patients without definitively curing the disease. To analyze life circumstances and quality of life QoL a large German MG cohort was investigated. Methods and Sample In cooperation with the German Myasthenia Association 2 150 patients with confirmed MG were asked to respond to a mailed questionnaire. The standardized questions related to demographic data impairments therapeutic course use of complementary therapies illness-related costs and quality of life SF-36 . In total 1 518 patients participated yielding a response rate of 70.6 . The average age was 56.7 years and the proportion of females 58.6 . Results Despite receiving recommended therapy many patients still suffered from MG-related impairments. In particular mobility and mental well-being were reduced moreover quality of life was markedly reduced. Stepwise linear regression analysis revealed illness stability impairments mental conditions comorbid diseases and employment to be determinants of QoL. Conclusion Results indicate that despite prolonged life expectancy among MG patients health-related quality of life is low. This outcome resulted mainly from impaired mobility and depression. Physical and mental well-being might be improved by additional therapy options. Additionally health care resources could be used more efficiently in these patients. Background Myasthenia gravis MG is a chronic autoimmune neuromuscular disease. The annual incidence is reported as being 0.25-4 patients per 100 000 residents with a prevalence of 8-15 patients per 100